Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)	Public Offering [Member] Common Stock [Member]	Public Offering [Member]	The 2019 Share Purchase Agreement [Member] Common Stock [Member]	The 2019 Share Purchase Agreement [Member]	The 2018 ATM Offering [Member] Common Stock [Member]	The 2018 ATM Offering [Member]	The 2018 Purchase Agreement [Member] Common Stock [Member]	The 2018 Purchase Agreement [Member]	The 2017 Purchase Agreement [Member] Common Stock [Member]	The 2017 Purchase Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017											27,502,000
Balance at Dec. 31, 2017											$ 231,923,000	$ 29,365,000	$ (4,316,000)	$ (246,770,000)	$ 10,202,000
Common shares issued (in shares)					2,017,000	2,017,046	170,000		5,232,000	5,231,953
Common shares issued					$ 6,818,000	$ 6,818,000	$ 600,000	$ 600,000	$ 14,995,000	$ 14,995,000
Common shares issued upon exercise of stock options (in shares)											96,000
Common shares issued upon exercise of stock options											$ 379,000	(160,000)			219,000
Stock-based compensation												3,695,000			3,695,000
Other comprehensive gain (loss)													3		3
Net loss														(22,607,000)	(22,607,000)
Balance (in shares) at Sep. 30, 2018											35,017,000
Balance at Sep. 30, 2018											$ 254,715,000	32,900,000	(4,313,000)	(269,377,000)	13,925,000
Balance (in shares) at Dec. 31, 2018											38,162,000
Balance at Dec. 31, 2018											$ 261,072,000	32,963,000	(4,316,000)	(275,638,000)	$ 14,081,000
Common shares issued (in shares)	11,500,000		171,000		77,000	77,349	5,502,000
Common shares issued	$ 19,594,000	$ 19,594,000	$ 360,000	$ 360,000	$ 178,000	$ 178,000	$ 10,000,000	$ 10,000,000
Common shares issued upon exercise of stock options (in shares)											34,000				34,000
Common shares issued upon exercise of stock options											$ 60,000	(24,000)			$ 36,000
Common shares issued on redemption of restricted share units (in shares)											40,000
Common shares issued on redemption of restricted share units											$ 80,000	(80,000)
Stock-based compensation												1,734,000			1,734,000
Other comprehensive gain (loss)													13,000		13,000
Net loss														(18,568,000)	(18,568,000)
Balance (in shares) at Sep. 30, 2019											55,486,000
Balance at Sep. 30, 2019											$ 291,344,000	$ 34,593,000	$ (4,303,000)	$ (294,206,000)	$ 27,428,000